Abstract:Aims Evidence from genetics, post mortem and animal studies suggest that N-Methyl-D-Aspartate Receptor (NMDAR) hypofunction has an important role in the pathophysiology of psychosis. However, it is not known if NMDAR activity is altered in the early stages of psychosis or if this links to symptom severity. Our aim was to investigate NMDAR availability in first-episode psychosis (FEP) and determine if it links to symptom severity. The NMDAR hypofunction hypothesis of schizophrenia was initially proposed in the 1990s on the basis of observations that ketamine and phencyclidine (PCP) induced the full range of schizophrenia-like symptoms (positive, negative and cognitive) when given to healthy participants and also that they worsen symptoms in patients with schizophrenia. Method We recruited 40 volunteers, including 21 patients with schizophrenia from early intervention services in London (12 antipsychotic-free and 9 receiving antipsychotic medication) and 19 matched healthy controls. The uptake of an NMDAR selective ligand, [18F]GE179, was measured using positron emission tomography (PET) and indexed using the distribution volume ratio (DVR) and volume of distribution (VT, in millilitres per cubic centimetre) of [18F]GE179 in the hippocampus and additional exploratory regions (anterior cingulate cortex (ACC), thalamus, striatum and temporal lobe). Symptom severity was measured using the Positive and Negative Syndrome Scale (PANSS). Result A total of 37 individuals were included in the analyses (mean [SD] age of controls, 26.7 [4.5] years; mean [SD] age of patients, 25.3 [4.9] years). There was a significant reduction in hippocampal DVR in the patients with schizophrenia relative to healthy controls (p = 0.02, Cohen's d = 0.81). Although the VT of [18F]GE179 was lower in absolute terms in patients, there was no significant effect of group on VT in the hippocampus (p = 0.15, Cohen's d = 0.49) or the exploratory brain regions. There was a negative association between hippocampal DVR and total PANSS symptoms (rho = –0.47, p = 0.04), depressive symptoms (rho = –0.67, p = 0.002), and general PANSS symptoms (rho = –0.74, p = 0.001). Conclusion These results indicate lower hippocampal NMDAR levels in schizophrenia relative to controls with a large effect size, and that lower NMDAR levels are associated with greater levels of symptom severity. These findings are consistent with the role of NMDAR hypofunction in the pathophysiology of schizophrenia; however, further work is required to test specificity and causal relationships.

Replication of the Abnormal Niacin Response in First Episode Psychosis Measured Using Laser Doppler Flowmeter

A potential objective marker in first-episode schizophrenia based on abnormal niacin response

Identification of Adolescent Patients with Depression Via Assessment of the Niacin Skin Flushing Response.

Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis

Neuronal Dysfunction in Individuals at Early Stage of Schizophrenia, A Resting-State Fmri Study

Comparison of Niacin Skin Flush Response in Patients with Schizophrenia and Bipolar Disorder

Attenuated and delayed niacin skin flushing in schizophrenia and affective disorders: A potential clinical auxiliary diagnostic marker

Membrane fatty acids, niacin flushing and clinical parameters

[Test for abnormal niacin response syndrome in schizophrenia: reclaiming the oral route]

N-Methyl-D-Aspartate Receptor binding in First-Episode Psychosis: A PET brain imaging study

Attenuated Niacin Skin Flushing Response in Children and Adolescents with Mental Disorders: A Transdiagnostic Early Warning Marker

N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients.

Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population.

Relationships Between Dorsolateral Prefrontal Cortex Metabolic Change and Cognitive Impairment in First-Episode Neuroleptic-Naive Schizophrenia Patients.

Plasma neurofilament light chain is not elevated in people with first-episode psychosis or those at ultra-high risk for psychosis

N-Methyl-d-Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients with Schizophrenia

Elevated Serum Anti-Nmda Receptor Antibody Levels in First-Episode Patients with Schizophrenia

Causal associations between niacin bluntness and schizophrenia: a GWAS and Mendelian randomization study

Altered neutrophil-to-lymphocyte ratio in patients with non-affective first episode psychosis and its relationship with symptom severity and cognitive impairment

Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives

Altered HCAR3 Expression May Underlying the Blunted Niacin Responses of the Psychiatric Disorders and the Risk of Schizophrenia.